Skip to main content
Call AIBook a demo

ICD-10-CM D75.81: Myelofibrosis

D75.81 is the billable ICD-10-CM code for myelofibrosis, in category D75 (Other and unspecified diseases of blood and blood-forming organs) of the Other disorders of blood and blood-forming organs section. As a principal diagnosis it groups to MS-DRG 820 Lymphoma and Leukemia with Major O.R. Procedures with MCC, MS-DRG 821 Lymphoma and Leukemia with Major O.R. Procedures with CC, MS-DRG 822 Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC (MDC 17 MDC 17: Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms). It maps to HCC 19 (Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers) in CMS-HCC V28. As a secondary diagnosis it is a CC, excluded with 133 principal diagnoses. 26 LCD billing and coding articles list it as covered.

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ICD-10-CM code descriptions: FY2027 (effective October 1, 2026); IPPS Table 5 (MS-DRG weights): v44 FY2027 (final rule + CN3) (effective October 1, 2026); ICD-10-CM to HCC mapping: PY2027 initial ICD-10-CM mappings (dates of service 2026) (payment year 2027); Medicare Coverage Database billing and coding articles: MCD release October 8, 2026 (effective October 4, 2026). Next CMS release: FY2028 code files, effective October 1, 2027 for the ICD-10-CM code descriptions; FY2028 final rule (August 2027), effective October 1, 2027; an April 1 interim grouper update when CMS issues one for the IPPS Table 5 (MS-DRG weights); PY2028 advance notice (February 2027) and the PY2027 midyear final mapping (spring 2027) for the ICD-10-CM to HCC mapping; weekly, every Thursday for the Medicare Coverage Database billing and coding articles.

Code
D75.81
billable FY2027 ICD-10-CM code
Category
D75 Other and unspecified diseases of blood and blood-forming organs
Chapter
3: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (D50-D89)
CC/MCC (MS-DRG v44)
CC
CMS-HCC V28
HCC 19
POA reporting
Required

Tabular list notes for D75.81

The tabular list has no notes on D75.81 itself; the notes below apply from its parent headings.

Inherited from D75 (Other and unspecified diseases of blood and blood-forming organs)

Excludes2 (not part of this condition, may be coded together)
  • acute lymphadenitis (L04.-)
  • chronic lymphadenitis (I88.1)
  • enlarged lymph nodes (R59.-)
  • hypergammaglobulinemia NOS (D89.2)
  • lymphadenitis NOS (I88.9)
  • mesenteric lymphadenitis (acute) (chronic) (I88.0)

MS-DRG grouping when D75.81 is the principal diagnosis

MS-DRG v44 groups for D75.81 as principal diagnosis
MDCMS-DRGs
17 MDC 17: Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms820821822823824825840841842

The final group also depends on procedures, secondary diagnoses and discharge status; the MS-DRG lookup for D75.81 shows the full grouping logic.

CC/MCC status and inpatient edits

As a secondary diagnosis, D75.81 is a CC under MS-DRG v44, unless the principal diagnosis is one of the 133 codes in its exclusion list. Check D75.81 against a principal diagnosis.

  • Present on admission: a POA indicator is required on inpatient claims.
  • Medicare Code Editor: manifestation code, not allowed as principal diagnosis.

CMS-HCC V28 risk adjustment

In the PY2027 mapping, D75.81 maps to HCC 19 (Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers). The HCC lookup shows the RAF weight and the hierarchy.

LCD billing and coding articles that list D75.81

26 current Medicare billing and coding articles list D75.81 among the diagnoses that support medical necessity for the services they cover.

For teams evaluating QuickIntell software

Evaluate software for diagnosis coding review

If your team codes diagnoses at volume, review how QuickCode supports qualified coder review of documentation, specificity queries and the billing handoff. Confirm the code sets, settings and reviewer responsibilities during evaluation; a code reference is not a coding determination for a patient.

Evaluate QuickCode for diagnosis codingSee risk adjustment review
Book a software demoAsk about a software workflow

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does ICD-10-CM D75.81 mean?

D75.81 means myelofibrosis. It is one of 13 billable codes under D75, other and unspecified diseases of blood and blood-forming organs.

Which MS-DRG does D75.81 group to?

As the principal diagnosis, D75.81 groups to MS-DRG 820 Lymphoma and Leukemia with Major O.R. Procedures with MCC, MS-DRG 821 Lymphoma and Leukemia with Major O.R. Procedures with CC, MS-DRG 822 Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC (MDC 17 MDC 17: Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms) under MS-DRG v44, before procedures and secondary diagnoses are applied.

Does D75.81 map to an HCC?

Yes: HCC 19, Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers, in the PY2027 CMS-HCC V28 mapping.

Is D75.81 a CC or MCC?

D75.81 is a CC under MS-DRG v44; 133 principal diagnoses exclude it.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-10-10. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The descriptor and notes are reproduced from the FY2027 ICD-10-CM files; MS-DRG, CC/MCC and HCC facts come from the CMS FY2027 and PY2027 tables. Code from the medical record and the ICD-10-CM Official Guidelines. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.